X

Russia and China have applied for registration of a joint vaccine against COVID-19

Date of publication: 15 March 2021

According to the Chinese Ambassador to Russia Zhang Hanhui, the coronavirus vaccine developed by the Chinese company CanSinoBiologics and the Russian company Petrovax is successfully passing the third phase of clinical trials, Interfax reports.

Referring to him, the application for registration of the drug in Russia has already been submitted, and confirmation is expected from the relevant Russian authorities.

In the course of testing of the joint Ad5-nCoV vaccine in Russia, positive data were obtained.

The issue of cooperation is being considered by the manufacturer of Sputnik V and Chinese enterprises. The Russian Ministry of Health has already approved the application for registration of the Chinese drug Azifuding.

The countries cooperate in such areas as epidemic prevention and control, diagnosis and treatment, testing, research and development of vaccines and medicines, and work is underway on several dozen projects

According to the official representative of the Chinese Foreign Ministry, Zhao Lijian, Beijing is ready to join forces with Moscow to further combat the coronavirus pandemic, in order to jointly ensure the health of all mankind. The Chinese authorities consider such interaction very productive, reports TASS.

So, at a regular briefing, the diplomat commented on the statements of the press secretary of the President of the Russian Federation Dmitry Peskov about the Russian-Chinese partnership.

China will counteract the pandemic as long as there are no coronavirus-infected people left in the world. The parties actively exchange experience, jointly developing vaccines, as well as fighting all kinds of “political viruses”.

Recall, during the announcement ceremony of the winners of the international professional photo contest News Photo Awards. At the TASS headquarters, Peskov expressed gratitude to the People’s Republic of China for its assistance and cooperation during the pandemic.



Comments

0

Read on the topic